Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Publications: details revised at 1 of 2 entriesv8
  2. Enrollment target: estimated 64 to confirmed 52v7
  3. Trial status: Recruiting to Completed
    • Site details revised
    v6
  4. Eligibility criteria revised
    • Study description revised
    v5
  5. Study description shortened, about 13 words
    • Site contact updated
    • Study title shortened, about 9 words
    • Eligibility criteria shortened, about 1 word
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Phase: Phase 4 to Phase 2
    • Interventions: mementine (Drug) to memantine (Drug)
    • Site contact updated
    v3
  2. Phase: Phase 2 to Phase 4
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2005
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this trial is to assess the efficacy and tolerability of memantine (anti-excitotoxic, neuroprotective treatment currently used in Alzheimer's disease \[AD\]) in frontotemporal dementia patients after a one-year treatment.
Trial Details
NCT Number NCT00200538
Lead Sponsor Nantes University Hospital
Conditions
(from sponsor)		 Dementia
Related terms Dementia, Frontotemporal Dementia
Enrollment 52 participants
Start Date
Updated on ClinicalTrials.gov